{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["64"],"submitter":["Kravutske H"],"pubmed_abstract":["<h4>Purpose</h4>Investigating real-world outcomes of moderately hypofractionated radiotherapy (hypoRT) in elderly and multimorbid stage IIB-IIIC non-small-cell lung cancer (NSCLC) patients ineligible for concurrent chemoradiation.<h4>Methods</h4>We retrospectively analysed 70 patients with primary or recurrent stage IIB-IIIC NSCLC (TNM, 8th edition). HypoRT was administered to a total dose of 38-56 Gy in 10-17 fractions (2.5-3.8 Gy/fraction). Patterns of recurrence, survival outcome, and toxicity were assessed.<h4>Results</h4>Seventy patients, with a median age of 76.4 years (range: 51.6-88.2 years), who received hypoRT between August 2015 and September 2022, were reviewed. At baseline, the median Charlson Comorbidity Index (CCI) with oncological diagnosis was 8 (range: 3-13). With a media"],"journal":["Acta oncologica (Stockholm, Sweden)"],"pagination":["957-965"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12308537"],"repository":["biostudies-literature"],"pubmed_title":["Real-world insights into moderately hypofractionated thoracic radiotherapy in elderly and multimorbid patients with stage II/III NSCLC: a retrospective study."],"pmcid":["PMC12308537"],"pubmed_authors":["Tufman A","Kravutske H","Kauffmann-Guerrero D","Mansoorian S","Kasmann L","Manapov F","Richlitzki C","Schmidt-Hegemann NS","Reinmuth N","Dinkel J","Eze C","Lehmann J","Belka C","Gaus R"],"additional_accession":[]},"is_claimable":false,"name":"Real-world insights into moderately hypofractionated thoracic radiotherapy in elderly and multimorbid patients with stage II/III NSCLC: a retrospective study.","description":"<h4>Purpose</h4>Investigating real-world outcomes of moderately hypofractionated radiotherapy (hypoRT) in elderly and multimorbid stage IIB-IIIC non-small-cell lung cancer (NSCLC) patients ineligible for concurrent chemoradiation.<h4>Methods</h4>We retrospectively analysed 70 patients with primary or recurrent stage IIB-IIIC NSCLC (TNM, 8th edition). HypoRT was administered to a total dose of 38-56 Gy in 10-17 fractions (2.5-3.8 Gy/fraction). Patterns of recurrence, survival outcome, and toxicity were assessed.<h4>Results</h4>Seventy patients, with a median age of 76.4 years (range: 51.6-88.2 years), who received hypoRT between August 2015 and September 2022, were reviewed. At baseline, the median Charlson Comorbidity Index (CCI) with oncological diagnosis was 8 (range: 3-13). With a media","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-03-17T15:51:07.896Z","creation":"2025-08-17T03:05:52.732Z"},"accession":"S-EPMC12308537","cross_references":{"pubmed":["40709481"],"doi":["10.2340/1651-226X.2025.43496"]}}